PDCD1 and gastric cancer: In fact, Kamada et al. revealed the presence of highly proliferative, suppressive effector Treg cells in GC patients undergoing hyperprogressive disease after anti-PD-1 treatment, suggesting the therapy’s undesired effects on Tregs (Figure 1B) (Kamada et al., 2019).